FDA approves Regeneron antibody cocktail for COVID-19 prevention

The FDA revised its emergency use authorization for Regeneron’s COVID-19 antibody cocktail July 30, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.

Advertisement

The treatment, a cocktail of casirivimab and imdevimab, was granted FDA emergency use authorization in November.

When announcing the revision to its emergency approval, the FDA stipulated that the antibody cocktail is authorized as a COVID-19 prophylaxis only for individuals who have been exposed to the virus. The agency also said the treatment is not a substitute for a COVID-19 vaccine.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.